Abstract
ß-Lapachone is an ortho naphthoquinone, originally isolated from a tree whose extract has been used medicinally for centuries. Recent investigations suggest its potential application against numerous diseases. Its lethality at micromolar (μm) concentrations against a variety of cancer cells in culture indicates its potential against tumor growth. A few experiments with positive results have been performed that apply the compound to tumors growing in animals. Particularly promising is the remarkably powerful synergistic lethality between ß-lapachone and taxol against several tumor cell lines implanted into mice; the mice did not appear to be adversely affected. Enhanced lethality of X-rays and alkylating agents to tumor cells in culture was reported when ß-lapachone was applied during the recovery period, because of inhibition of DNA lesion repair. Clinical trials are still to be initiated. The detailed mechanism of cell death induced by ß-lapachone remains for investigation. DNA topoisomerase I was the first biochemical target of ß-lapachone to be discovered, although its role in cell death is not clear. A proposed mechanism of cell death is via activation of a futile cycling of the drug by the cytoplasmic two-electron reductase NAD(P) H: quinone oxidoreductase, also known as NQO1, DTdiaphorase and Xip3. Death of NQO1 expressing cells is prevented by the NQO1 inhibitor dicoumarol, and cells with low NQO1 are resistant. At higher drug concentrations the production of reactive oxygen species (ROS) appears to be responsible. Furthermore, this process is p53- and caspase- independent. Either apoptotic or necrotic cell death can result, as reported in various studies performed under differing conditions. ß-Lapachone is one of a few novel anticancer drugs currently under active investigation, and it shows promise for chemotherapy alone and especially in combinations.
Keywords: cancer therapy, lapachone, cytoplasmic two-electron reductase, prostate tumor cells, dna-related enzymes, proteases, isolated mitochondria
Current Cancer Drug Targets
Title: Cancer Therapy with ß-Lapachone
Volume: 2 Issue: 3
Author(s): Arthur B. Pardee, You Zhi Li and Chiang J. Li
Affiliation:
Keywords: cancer therapy, lapachone, cytoplasmic two-electron reductase, prostate tumor cells, dna-related enzymes, proteases, isolated mitochondria
Abstract: ß-Lapachone is an ortho naphthoquinone, originally isolated from a tree whose extract has been used medicinally for centuries. Recent investigations suggest its potential application against numerous diseases. Its lethality at micromolar (μm) concentrations against a variety of cancer cells in culture indicates its potential against tumor growth. A few experiments with positive results have been performed that apply the compound to tumors growing in animals. Particularly promising is the remarkably powerful synergistic lethality between ß-lapachone and taxol against several tumor cell lines implanted into mice; the mice did not appear to be adversely affected. Enhanced lethality of X-rays and alkylating agents to tumor cells in culture was reported when ß-lapachone was applied during the recovery period, because of inhibition of DNA lesion repair. Clinical trials are still to be initiated. The detailed mechanism of cell death induced by ß-lapachone remains for investigation. DNA topoisomerase I was the first biochemical target of ß-lapachone to be discovered, although its role in cell death is not clear. A proposed mechanism of cell death is via activation of a futile cycling of the drug by the cytoplasmic two-electron reductase NAD(P) H: quinone oxidoreductase, also known as NQO1, DTdiaphorase and Xip3. Death of NQO1 expressing cells is prevented by the NQO1 inhibitor dicoumarol, and cells with low NQO1 are resistant. At higher drug concentrations the production of reactive oxygen species (ROS) appears to be responsible. Furthermore, this process is p53- and caspase- independent. Either apoptotic or necrotic cell death can result, as reported in various studies performed under differing conditions. ß-Lapachone is one of a few novel anticancer drugs currently under active investigation, and it shows promise for chemotherapy alone and especially in combinations.
Export Options
About this article
Cite this article as:
Pardee B. Arthur, Li Zhi You and Li J. Chiang, Cancer Therapy with ß-Lapachone, Current Cancer Drug Targets 2002; 2 (3) . https://dx.doi.org/10.2174/1568009023333854
DOI https://dx.doi.org/10.2174/1568009023333854 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Intrabody-Based Approaches to Cancer Therapy: Status and Prospects
Current Medicinal Chemistry Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Polymers and Drug Delivery Systems
Current Drug Delivery The Role of Genistein and Synthetic Derivatives of Isoflavone in Cancer Prevention and Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Anticancer Macromolecular Prodrugs in Clinical Trials - an Update (Guest Editor: Felix Kratz)]
Current Bioactive Compounds Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Momordica charantia Seed and Aryl Extracts Potentiate Growth Inhibition and Apoptosis by Dual Blocking of PI3K/AKT and MAPK Pathways as a Downstream Target of EGFR Signaling in Breast Cancer Cells
Current Nutrition & Food Science Methods for Biomarker Verification and Assay Development
Current Proteomics Canonical Matches of Human MicroRNAs with mRNAs: A Broad Matrix of Position and Size
MicroRNA Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Chemical and Medicinal Versatility of Dithiocarbamates: An Overview
Mini-Reviews in Medicinal Chemistry Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy
Current Medicinal Chemistry Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience A Review of the Relationships Between Endogenous Sex Steroids and Incident Ischemic Stroke and Coronary Heart Disease Events
Current Cardiology Reviews Past, Present and Future of Targeted Therapy in Solid Tumors
Current Cancer Drug Targets Implication of Raft Microdomains in Drug Induced Apoptosis
Current Medicinal Chemistry - Anti-Cancer Agents Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Current Drug Targets